Differential Effects of Partial and Complete Loss of TREM2 on Microglial Injury Response and Tauopathy [RNA-Seq]

Late-onset Alzheimer’s disease is the most common form of dementia. A rare hemizygous variant in a microglial-expressed gene, Triggering Receptor Expressed on Myeloid Cells 2 (TREM2), significantly increases risk for late-onset Alzheimer’s disease. This variant is thought to cause loss of function, inducing TREM2 haploinsufficiency. The ramifications of TREM2 haploinsufficiency on microglial function and tau pathology are major gaps in the field. We find that in contrast to the protective effects of complete TREM2 deficiency, TREM2 haploinsufficiency exacerbates tau pathology, inflammation, and atrophy at a late stage of disease in a mouse model of tauopathy. The differential effects of partial and complete loss of TREM2 are important considerations for TREM2-targeted therapeutic strategies. RNA was isolated from cortical brain tissue from 8- to 9-month-old TREM2+/+, P301S+ TREM2+/+, P301S+ TREM2+/- and P301S+ TREM2-/- mice using the Rneasy mini kit.